Synaptogenix, Inc. (NASDAQ:SNPX) Sees Significant Decline in Short Interest

83.3% from the April 30th total of 13,600 shares. Based on an average daily volume of 80,000 shares, the short-interest ratio is presently 0.0 days. The company has a market capitalization of $35.29 million and a price-to-earnings ratio of -1.13. Synaptogenix, Inc. has a 52 week low of $0.72 and

() saw a significant drop in short interest during the month of may. On May 15th there were 2,300 short shares. This is a decrease of 94.1% compared to the total of 39,00 shares on April 30th. About 0.0% of shares are short-sold. The days-tocover ratio, based on an average daily volume of 59.800 shares, is currently 0.0.

Synaptogenix stock down 4.5 %

On Friday, the stock fell $0.04 to $0.85. The stock of the company traded 28,403 shares compared to an average of 71840. The company has a market capitalization of $6.25m, a P/E of -0.41 as well as a beta value of 1.26. The company's fifty-day moving price is $0.85, and its 200-day moving price is $1.98. Recently, hedge funds and institutional investors have made significant changes to their holdings in the company. Platform Technology Partners increased its holdings in Synaptogenix shares by 56.8% during the fourth quarter. Platform Technology Partners owns 25,138 of the stock worth $29,000, after buying 9,106 additional shares during the last quarter. Prelude Capital Management LLC increased its stake in Synaptogenix shares by 13.9% during the second quarter. Prelude Capital Management LLC owns 14,364 of the company stock, valued at $75,000, after buying an additional 1,750 in the last quarter. In the second quarter, Renaissance Technologies LLC purchased a new share of Synaptogenix valued at $83,000. Vanguard Group Inc. increased its stake in Synaptogenix shares by 2.6% during the third quarter. Vanguard Group Inc. owns 222 495 shares worth $1,491,000, after buying an additional 5,659 in the last quarter. Institutional investors and hedge fund own 6.99% the company's shares.

Synaptogenix Company profile

Get Rating

Synaptogenix, Inc is a biopharmaceutical firm that has product candidates under pre-clinical or clinical development. It is focused on developing a platform of products based on a drug called Bryostatin-1 to treat Alzheimer's. The company also evaluates therapeutic applications of bryostatin in other neurodegenerative and cognitive diseases, including fragile X syndrome and multiple sclerosis. offers a FREE daily email newsletter